MCF Advisors’s AstraZeneca AZN Stock Holding History

MCF Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-75	Closed	-$14.2K	–	508
2026 Q2	$14.2K	Hold	75	–	–	﹤0.01%	973
2026 Q1	$14.8K	Buy	75 +34	+83%	+$6.56K	﹤0.01%	884
2025 Q4	$7.54K	Buy	41 +38	+1,267%	+$6.66K	﹤0.01%	885
2025 Q3	$384	Buy	+3	New	+$454	﹤0.01%	927
2025 Q1	–	Sell	-7	Closed	-$852	–	922
2024 Q4	$852	Buy	+7	New	+$980	﹤0.01%	930
2023 Q3	–	Sell	-150	Closed	-$21.5K	–	924
2023 Q2	$21.5K	Hold	150	–	–	﹤0.01%	469
2023 Q1	$20.8K	Hold	150	–	–	﹤0.01%	470
2022 Q4	$20.3K	Hold	150	–	–	﹤0.01%	445
2022 Q3	$16K	Hold	150	–	–	﹤0.01%	489
2022 Q2	$20K	Buy	+150	New	+$19.7K	﹤0.01%	440

Other funds holding AZN

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

MCF Advisors's AZN Position: Q3 2026 in Review

MCF Advisors sold out of AstraZeneca (AZN) in Q3 2026, closing a stake of 75 shares — an estimated $14.2K sold.

MCF Advisors first reported a position in AZN in Q2 2022 and held it in 10 quarters. The position peaked at $21.5K in Q2 2023. 1,062 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

MCF Advisors reported no remaining AstraZeneca position as of Q3 2026 after selling out during the quarter.
MCF Advisors sold 75 AstraZeneca shares in Q3 2026, an estimated $14.2K.
MCF Advisors first reported a position in AstraZeneca in Q2 2022 and held it in 10 quarters.
MCF Advisors's AstraZeneca position peaked at $21.5K in Q2 2023.
1,062 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on MCF Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.